Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
166.4 EUR | -0.66% | -0.78% | +15.44% |
Jun. 04 | Global markets live: ASML, Intel, Microsoft, Tesla, J&J, Gitlab | |
Jun. 04 | MERCK KGAA : JP Morgan remains its Buy rating | ZD |
Summary
- The company presents an interesting fundamental situation from a short-term investment perspective.
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The company returns high margins, thereby supporting business profitability.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- The firm trades with high earnings multiples: 24.13 times its 2024 earnings per share.
- The company's enterprise value to sales, at 3.7 times its current sales, is high.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+15.44% | 79.25B | A | ||
+14.26% | 9.15B | A- | ||
-13.94% | 4.9B | A- | ||
+48.58% | 4.46B | - | ||
+14.10% | 4.09B | B- | ||
+19.66% | 2.49B | B | ||
-25.55% | 2.17B | C- | ||
+18.39% | 2.1B | - | - | |
-39.57% | 1.89B | - | ||
-0.50% | 1.64B | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- MRK Stock
- Ratings Merck KGaA